SCHEMBL19629151

SCHEMBL19629151

O=C1/C(=C/c2cccc(Br)c2)CN(CCc2ccccc2)C/C1=C\c1cccc(Br)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 6/20 0.69
HSD11B1 P28845 1/20 0.56
ACHE P22303 5/20 0.53
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DRD3 P35462 1/20 0.47
XDH P47989 1/20 0.45
NPC1 O15118 1/20 0.45
P4HB P07237 1/20 0.45
PAX8 Q06710 1/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21354054 1.00 CARM1 (0.69) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL19615423 1.00 CARM1 (0.69) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL21353874 0.93 CARM1 (0.71) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL19629246 0.93 CARM1 (0.71) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL19629105 0.87 CARM1 (0.68) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL29711818 0.87 CARM1 (0.68) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL19615995 0.87 CARM1 (0.68) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL19615994 0.87 CARM1 (0.68) CARM1HSD11B1ACHEMEN1KMT2A
SCHEMBL11723898 0.87 CARM1 (0.67) CARM1ACHEMEN1KMT2AALDH1A1
SCHEMBL11723894 0.87 CARM1 (0.67) CARM1ACHEMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458607-B1 METHOD FOR THE PROGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA EPI C S R L (IT) 2021-10-06 EP disclosed
US-20190284635-A1 METHOD FOR THE PROGNOSIS AND/OR TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA EPI-C S.R.L. (IT) 2019-09-19 US disclosed
WO-2017198870-A1 METHOD FOR THE PROGNOSIS AND/OR TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA EPI-C S.R.L. (IT) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284635-A1 METHOD FOR THE PROGNOSIS AND/OR TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA EZH2, KAT2A, EHMT2 CARM1 56/4885HSD11B1 2988/4885ACHE 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.